Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD19-chimeric Antigen Receptor T Cells”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07779018
What this trial is testing

CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy

Who this might be right for
Lymphoma
Liping Dou 30
Early research (Phase 1)Looking for participantsNCT06173518
What this trial is testing

CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Who this might be right for
Relapsed or Refractory B Cell Acute Lymphoblastic LeukemiaRelapsed or Refractory B Cell Non-Hodgkin Lymphoma
Autolus Limited 30
Very early researchLooking for participantsNCT07470073
What this trial is testing

A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults

Who this might be right for
ALL (Acute B-Lymphoblastic Leukemia)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 18
Early research (Phase 1)Active Not RecruitingNCT03085173
What this trial is testing

A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies

Who this might be right for
Chronic Lymphocytic Leukemia (CLL)RelapsedRefractory
Memorial Sloan Kettering Cancer Center 39
Early research (Phase 1)Study completedNCT04488354
What this trial is testing

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

Who this might be right for
Relapsed/Refractory B-cell LymphomasDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)+9 more
Calibr, a division of Scripps Research 16
Early research (Phase 1)UnknownNCT05640713
What this trial is testing

Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy

Who this might be right for
Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
Henan Cancer Hospital 12
Not applicableUnknownNCT03327285
What this trial is testing

C-CAR011 Treatment in Subjects With ALL After HSCT

Who this might be right for
Acute Lymphoblastic Leukemia(ALL)
Peking University People's Hospital 40
Early research (Phase 1)Study completedNCT05149391
What this trial is testing

C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma

Who this might be right for
B Cell Non-Hodgkin's Lymphoma
Peking University 3
Testing effectiveness (Phase 2)Looking for participantsNCT06428188
What this trial is testing

Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases

Who this might be right for
Autoimmune DiseasesSystemic Lupus ErythematosusSystemic Lupus Erythematosus Acute+1 more
Essen Biotech 60
Testing effectiveness (Phase 2)Ended earlyNCT06400303
What this trial is testing

KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

Who this might be right for
Systemic SclerosisSystemic Sclerosis - Diffuse CutaneousSystemic Sclerosis - 2013 ACR/EULAR Classification Criteria
Kyverna Therapeutics 3
Very early researchTemporarily pausedNCT06662227
What this trial is testing

Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors

Who this might be right for
B Cell LymphomaB Cell LeukemiaB Cell Malignancy
Wondercel Biotech (ShenZhen) 30
Testing effectiveness (Phase 2)UnknownNCT04649983
What this trial is testing

CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Who this might be right for
Leukemia, B-cellLymphoma, B-Cell
Chongqing Precision Biotech Co., Ltd 40
Early research (Phase 1)Not Yet RecruitingNCT06006741
What this trial is testing

Universal CAR-T Cells Targeting Multiple Myeloma

Who this might be right for
Multiple Myeloma in Remission
Shenzhen Geno-Immune Medical Institute 20
Testing effectiveness (Phase 2)Looking for participantsNCT07523542
What this trial is testing

SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus

Who this might be right for
REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUSLupus Nephritis
Beijing Biotech 24
Testing effectiveness (Phase 2)Ended earlyNCT06342960
What this trial is testing

KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Who this might be right for
Lupus NephritisLupus Nephritis - WHO Class IIILupus Nephritis - WHO Class IV
Kyverna Therapeutics 2
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07765524
What this trial is testing

A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL Amyloidosis

Who this might be right for
Primary Light Chain (AL) Amyloidosis
Shenzhen Fosun Kairos Biotechnology Co., Ltd. 32
Testing effectiveness (Phase 2)UnknownNCT03118180
What this trial is testing

CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma

Who this might be right for
Lymphoma
Zhejiang University 50
Testing effectiveness (Phase 2)Ended earlyNCT02794246
What this trial is testing

CART-19 Post-ASCT for Multiple Myeloma

Who this might be right for
Multiple Myeloma
University of Pennsylvania 6
Very early researchLooking for participantsNCT06346912
What this trial is testing

CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL

Who this might be right for
Acute Lymphoblastic Leukemia,B-CellNon-hodgkin Lymphoma,B Cell
Zhejiang University 20
Testing effectiveness (Phase 2)Looking for participantsNCT04844866
What this trial is testing

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Who this might be right for
Diffuse Large B-cell Lymphoma
Miltenyi Biomedicine GmbH 213
Next Page